Axovant Sciences (AXON), vTv Therapeutics (VTVT) Mechanisms Don't Overlap with Sola - Piper

November 23, 2016 11:22 AM EST
Get Alerts AXON Hot Sheet
Price: $12.50 +0.32%

Rating Summary:
    9 Buy, 0 Hold, 2 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 30 | Down: 30 | New: 23
Trade AXON Now!
Join SI Premium – FREE

Get daily under-the-radar research with's Stealth Growth Insider Get your 2-Wk Free Trial here.

Piper Jaffray analyst Charles Duncan said Lilly's solanezumab failure doesn't change their perception of risk for Axovant Sciences (NYSE: AXON) or vTv Therapeutics (NASDAQ: VTVT), noting these candidates have mechanisms that do not overlap with sola.

Duncan commented, "Today the Phase III trial of solanezumab, a mAb to A-Beta, didn't reach the primary endpoint of cognition improvement in mild Alzheimer’s Disease. Although we acknowledge that sentiment is challenged for AD drug development and will remain so until a clear win is seen, we’re defending our AD thesis and current Overweight thesis on AXON and VTVT. Our AD thesis has been to focus on candidates with differentiated MOAs, especially those with compelling clinical data to inform Phase III trial design without multiple changes to endpoints or patient criteria. Therefore, the sola’ news doesn't change our perception of risk for either AXON’s RVT-101 or VTVT’s azeliragon – these candidates have mechanisms that do not overlap with sola’. In addition, while there are many contrasts between MINDSET and STEADFAST vs. EXPEDITION 3, the key one in our view is that MINDSET and STEADFAST are supported by positive, prospective Phase IIb datasets."

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, FDA, Trader Talk

Related Entities

Piper Jaffray, Charles Duncan

Add Your Comment